Tafamidis Disease Interactions
There are 2 disease interactions with tafamidis.
Tafamidis (applies to tafamidis) hypothyroidism
Moderate Potential Hazard, Moderate plausibility.
Tafamidis binds to transthyretin (TTR) at the thyroxine binding sites. The use of tafamidis may decrease serum concentrations of total thyroxine, without an accompanying change in thyroid stimulating hormone (TSH). The reduction in total thyroxine values is probably the result of reduced thyroxine binding to or displacement from transthyretin due to the high binding affinity of tafamidis to the TTR thyroxine receptor. No corresponding clinical findings consistent with hypothyroidism have been observed. Exercise care when using this agent in patients with hypothyroidism.
Tafamidis (applies to tafamidis) liver disease
Moderate Potential Hazard, Moderate plausibility.
The use of tafamidis in patients with moderate hepatic impairment (Child-Pugh Score of 7 to 9) demonstrated decreased systemic exposure (approximately 40%) and increased clearance (approximately 68%) when compared to healthy subjects. No clinically significant differences in the pharmacokinetics of tafamidis were observed in patients with mild hepatic impairment (Child Pugh Score of 5 to 6). Use caution when using this agent in patients with severe hepatic impairment as its effect is unknown.
Switch to professional interaction data
Tafamidis drug interactions
There are 33 drug interactions with tafamidis.
More about tafamidis
- tafamidis consumer information
- Check interactions
- Compare alternatives
- Reviews (15)
- Side effects
- Dosage information
- During pregnancy
- Drug class: transthyretin stabilizers
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Vyndamax
Vyndamax may be given to reduce death or hospitalization caused by heart problems in adults with ...
Tegsedi
Tegsedi (inotersen) is an RNA-targeting treatment that may be used to reduce the symptoms of ...
Vyndaqel
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer that may be given to reduce death or ...
Onpattro
Onpattro is used to treat polyneuropathy in adults with hereditary transthyretin-mediated ...
Amvuttra
Amvuttra is used to treat polyneuropathy associated with hereditary transthyretin-mediated ...
Wainua
Wainua (eplontersen) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Attruby
Attruby (acoramidis) tablets are used to treat cardiomyopathy of wild-type or hereditary ...
Eplontersen
Eplontersen (Wainua) is used to treat polyneuropathy of hereditary transthyretin-mediated ...
Vutrisiran
Vutrisiran is used to treat adults with nerve damage (polyneuropathy) caused by hereditary ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.